POMEZIA, Italy, Oct. 20, 2022 /PRNewswire/ -- Alfasigma S.p.A. has completed the acquisition of SOFAR S.p.A., thus officially starting the integration process of the two companies.
The transaction, which began last August and was scheduled to be completed in October 2022, has been successfully completed in full compliance with the planned schedule.
Alfasigma is one of the leading multinational pharmaceutical companies with a turnover of more than €1 billion in 2021, R&D facilities in Bologna and Pomezia, 3 production plants in Italy and 2 abroad, some 3,000 employees, an on-site presence in 17 markets and an indirect presence in some 70 countries.
SOFAR is an Italian pharmaceutical company dedicated to the research, production and marketing of medicines, medical devices and dietary supplements -with a long tradition and well known by professionals and patients- with a turnover of more than 100 million, 150 references marketed in more than 10 therapeutic areas and 300 employees worldwide.
In addition, SOFAR brings 54 years of history in the field of gastroenterology and a highly complementary product portfolio to that of Alfasigma.
"This acquisition", affirms Stefano Golinelli, president of Alfasigma, "will allow our company to consolidate itself in the Italian market and focus even more on the area of gastroenterology, adding to the ambitious growth strategy of our company and the will of my father, Cavaliere Marino Golinelli, of always looking to the future".
Both companies are strongly inclined towards innovation. SOFAR, in particular, has developed, through the Kilometro Rosso Science and Technology Park in Bergamo, a center of excellence in microbiota research, while Alfasigma is developing a portfolio of products focused on the gastrointestinal area.
The integration between the two companies, through the enhancement of their respective scientific knowledge, will allow an even more prominent position in the gastrointestinal area, an area in which SOFAR registers more than 80% of its sales.
"Alfasigma has a clear objective: to focus on innovation, to become stronger in the gastrointestinal area and to maximize the potential of the international market. We are one of the main pharmaceutical multinationals with Italian capital, we start from a solid and at the same time full present. of potential for the future, with great opportunities for improvement", explained Francesco Balestrieri, CEO of Alfasigma and added, "We want to be more international, more specialized and more focused on the gastroenterology area. We still have a wide margin to develop the current portfolio Starting with the international expansion of the Consumer Healthcare division, physiological growth will take place alongside significant inorganic development, both globally and in Europe, in order to develop our R&D portfolio in specialty gastro areas. The goal is to double our income in 10 years."
The synergy between the two companies will allow to expand the range of Alfasigma products in Italy and in foreign markets, adding SOFAR products to its portfolio: Pentacol, Enterolactis and Gerdoff for the gastrointestinal area; Cistiflux and Siler for the gynecological/urological area.
For more information: www.alphasigma.com
logo - link
View original content: enlace
